This is the peer reviewed version of the following article:

J. M. Dodd, C. Andersen, J. E. Dickinson, J. Louise, A. Deussen, R. M. Grivell, L. Voto, M. D. Kilby, R. Windrim, G. Ryan for the MCA Doppler Study Group

Fetal middle cerebral artery Doppler to time intrauterine transfusion in red-cell alloimmunization: a randomized trial

Ultrasound in Obstetrics and Gynecology, 2018; 51(3):306-312

which has been published in final form at http://dx.doi.org/10.1002/uog.18807

© 2017 ISUOG. Published by John Wiley & Sons Ltd.

This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

PERMISSIONS


Wiley's Self-Archiving Policy

Accepted (peer-reviewed) Version

The accepted version of an article is the version that incorporates all amendments made during the peer review process, but prior to the final published version (the Version of Record, which includes; copy and stylistic edits, online and print formatting, citation and other linking, deposit in abstracting and indexing services, and the addition of bibliographic and other material.

Self-archiving of the accepted version is subject to an embargo period of 12-24 months. The embargo period is 12 months for scientific, technical, and medical (STM) journals and 24 months for social science and humanities (SSH) journals following publication of the final article.

- the author's personal website
- the author's company/institutional repository or archive
- not for profit subject-based repositories such as PubMed Central

Articles may be deposited into repositories on acceptance, but access to the article is subject to the embargo period.

The version posted must include the following notice on the first page:

"This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving."

The version posted may not be updated or replaced with the final published version (the Version of Record). Authors may transmit, print and share copies of the accepted version with colleagues, provided that there is no systematic distribution, e.g. a posting on a listserv or automated delivery.

There is no obligation upon authors to remove preprints posted to not for profit preprint servers prior to submission.

5 November 2019

http://hdl.handle.net/2440/113905
**TITLE:** Fetal MCA Doppler to time intrauterine transfusions in red cell alloimmunisation: A randomised trial.

**SHORT TITLE:** MCA Doppler to time IUTs

**AUTHORS:**
Professor Jodie M DODD¹,²
Dr Chad ANDERSEN³
Professor Jan E DICKINSON⁴,⁵
Dr Jennie LOUISE¹,⁶
Ms Andrea DEUSSEN¹
Associate Professor Rosalie M GRIVELL¹,²,⁷
Professor Liliana VOTO⁸
Professor Mark D KILBY⁹
Professor Rory WINDRIM¹⁰
Professor Greg RYAN¹⁰
For the MCA Doppler Study Group.

**INSTITUTIONAL AFFILIATIONS:**
1. Discipline of Obstetrics and Gynaecology, and The Robinson Research Institute, The University of Adelaide, AUSTRALIA
2. Women’s and Babies Division, Women’s & Children’s Hospital, North Adelaide, AUSTRALIA
3. Department of Neonatology, Women’s and Children’s Hospital, North Adelaide, AUSTRALIA
4. School of Women’s and Infants’ Health, The University of Western Australia, Crawley, AUSTRALIA
5. Maternal Fetal Medicine, King Edward Memorial Hospital, Perth, AUSTRALIA
6. School of Population Health, The University of Adelaide, AUSTRALIA
7. Permanent Address: Flinders University, Department of Obstetrics & Gynaecology; Bedford Park, South Australia, AUSTRALIA
8. Fernandez Hospital, Buenos Aires, ARGENTINA
9. Birmingham Centre for Women’s & New Born Health, University of Birmingham, and the Fetal Medicine Centre, Birmingham Women’s Foundation Trust, Birmingham, UNITED KINGDOM
10. Fetal Medicine Unit, Mt Sinai Hospital, and University of Toronto, Toronto, CANADA

**CORRESPONDING AUTHOR:**
Professor Jodie M Dodd
The University of Adelaide,
Women’s and Children’s Hospital
72 King William Road
North Adelaide, South Australia, AUSTRALIA 5006
Phone: +61 8 8161 7619
Fax: +61 8 8161 7652
E-mail: jodie.dodd@adelaide.edu.au
WORD COUNT:
Abstract: 453/500
Text: 2870/3000 (Introduction 244 words; Discussion 837 words)

KEY WORDS:
Randomised trial
MCA Doppler PSV
Fetal anaemia
Intra-uterine fetal transfusion
Infant haemoglobin
Objectives: Red cell alloimmunisation affects up to 0.6% of all live births, and can be successfully treated with intrauterine fetal blood transfusion. Fetal middle cerebral artery (MCA) Doppler peak systolic velocity (PSV) is a non-invasive test, to identify fetal anaemia and requiring intrauterine transfusion (IUT). Traditionally, timing of subsequent IUTs has involved estimating a fall in fetal haematocrit of 1% per day, or a fall in fetal haemoglobin of 0.3g/dL per day.

The aim of this pragmatic multi-centre randomised trial was to evaluate whether Doppler MCA-PSV in the fetus that has undergone one IUT for anaemia secondary to red cell alloimmunisation was non-inferior to timing IUT by timing based on predicting the fall in fetal haematocrit or fetal haemoglobin, without compromising infant haemoglobin at birth.

Methods: We conducted an international, multi-centre randomised trial.

Women with pregnancies complicated by fetal anaemia secondary to red cell alloimmunisation (due to any antibody alone or in combination) as indicated by the need to undergo a single IUT were eligible for inclusion.

Women were randomised to the Timing of Transfusion by MCA-PSV Group (ultrasound determination of the fetal MCA-PSV, with a serial upward trend with values >1.5MoM considered indicative of the need for another IUT), or to the Timing of Transfusion by Prediction of the Fall in Fetal Haematocrit (Hct) Group (subsequent IUT’s timed according an estimated fall in fetal Hct of 1% per day or fetal haemoglobin of 0.3g/dL per day, to maintain the fetal haemoglobin between 7-10g/dL).

The primary study outcome was infant haemoglobin measured at birth.

The trial was registered on the Australian and New Zealand Clinical Trials Register (ACTRN12608000643370).
**Results:** We randomised 71 women (36 to the MCA-PSV Group; and 35 to the Fall in Fetal Hct. Group) from 13 centres in Australia, New Zealand, Canada, United Kingdom, Ireland, Belgium, and Argentina.

The median gestational age at randomisation was 30.3 weeks, and the majority of women were Caucasian and non-smokers; 9.9% of women had Kell alloimmunisation, and 14% of fetuses were hydropic at their first IUT.

There were no statistically significant differences between the two treatment groups with regards to mean haemoglobin at birth (MCA-PSV Group 103.6±38.2g/dL versus Fall in Fetal Hct Group 120.3±31.4g/dL; adjusted mean difference -15.6; 95% CI -32.4 to 1.3; p=0.070), or the number of IUTs performed after randomisation (MCA-PSV Group 1.75 (±1.79) versus Fall in Fetal Hct Group 1.80 (±1.32); adjusted relative risk aRR 0.88; 95% confidence interval (CI) 0.61 to 1.26; p=0.474). There were no statistically significant differences between the two groups in the risk of adverse infant outcomes related to alloimmunisation, or procedure related complications.

**Conclusions:** Both Doppler MCA-PSV measurement and estimating the fall in fetal haematocrit or haemoglobin can be used to time second and subsequent IUTs.
INTRODUCTION:

Middle cerebral artery (MCA) Doppler peak systolic velocity (PSV) identifies the fetus at risk of anaemia and requiring intrauterine transfusion (IUT). (1) Originally described by Mari, (2) a PSV above 1.5 multiples of the median (MoM) identified moderate or severe fetal anaemia with sensitivity 100%, and false positive rate (FPR) 12%. (2, 3) Despite limitations, (4) MCA-PSV is widely used, compares favourably with amniotic fluid bilirubin concentrations, (5) and has largely replaced serial amniocentesis in managing red cell alloimmunisation.

Traditionally, timing of subsequent IUTs involves estimating the rate of red cell destruction. (6-8) either by fall in fetal haematocrit, (9) or haemoglobin. (10) Correction of fetal anaemia following IUT normalises fetal MCA-PSV measurements, (11) extending potential use to time second and subsequent procedures. (10, 12-15)

However, as highlighted by Moise, this is not supported by available data. (16)

Detti and colleagues (13) used a MCA-PSV >1.69MoM to correctly identify all fetuses with severe anaemia following a single IUT, with a false positive rate of 6%. However, following two or more IUTs, MCA-PSV values above 1.5MoM have variably identified severe fetal anaemia with sensitivity between 84 and 100%, (10, 14, 15) with false positive rates of the order of 50%. (10, 15) Indeed, a recent study has indicated that, particularly after second IUTs, formulae to estimate red cell destruction are more accurate than MCA-PSV. (17)
We conducted a pragmatic trial to evaluate whether timing of second and subsequent IUTs with Doppler MCA-PSV was non-inferior to estimating the fall in fetal haematocrit or haemoglobin, without compromising haemoglobin at birth.
METHODS:

**Study Design:** A multi-centre, randomised controlled trial.

**Inclusion Criteria:** Women with a singleton pregnancy complicated by fetal anaemia secondary to red cell alloimmunisation from any red cell antibody as indicated by the need to have performed a single IUT were eligible to participate.

**Exclusion Criteria:** Pregnant women whose fetus had anaemia secondary to any other cause, or with known chromosomal anomalies were ineligible.

**Trial Entry:** Eligible women were identified after the decision was made to proceed with the first IUT, and provided written informed consent to participate.

**Randomisation:** We used an on-line randomisation service with computer generated schedule using balanced variable blocks, and stratification for the presence or absence of hydrops at first IUT, type of antibody (Kell versus other), and centre of birth. Women were randomised to **Timing of Transfusion by MCA-PSV Group** (with a serial upward trend and MCA-PSV values >1.5MoM indicative of the need for another IUT), or to the **Timing of Transfusion by Estimating the Fall in Fetal Hct Group** (subsequent IUT’s timed according an estimated fall in fetal Hct of 1% per day).

**Treatment Schedules:**

**Timing of Transfusion by MCA-PSV Group** - Women underwent serial ultrasound examinations performed in a standard fashion(3) and at a frequency determined by individual clinicians experienced in the management of fetal alloimmunisation. In
short, measurements were made in the absence of fetal breathing movements, with the woman in a semi-recumbent position. An axial section was obtained through the fetal brain, caudal to the level required for the measurement of the biparietal diameter, with identification of the middle cerebral artery using colour or power Doppler settings, and angle of insonation of 0-10 degrees. Angle correction did not exceed 30 degrees. The sample volume was placed near the internal carotid artery, and a measurement of the peak Doppler waveform taken after obtaining five representative waveforms. Consistent with practices within each participating fetal medicine unit, the MCA-PSV value was recorded on standardised, and an upward serial trend in values consistently >1.50MoM considered indicative of the need for IUT. The new identification of ascites and/or hydrops was additionally considered indicative of the need for IUT, regardless of the MCA-PSV value.

**Timing of Transfusion by Estimation of the Fall in Fetal Hct Group** - Women had the timing of IUTs planned using standard criteria to predict the rate of red cell destruction and development of anaemia, based on gestational age, haemoglobin prior to IUT, and haemoglobin at IUT completion. (6-8) A fall in fetal haematocrit of 1% per day, (9) or fetal haemoglobin of 0.3g/dL per day, was estimated, with IUT undertaken according to the usual practices within each center, to maintain the fetal haemoglobin between 7-10g/dL. (10)

**Both treatment groups:**
At a gestation beyond 24 weeks, women were administered antenatal corticosteroids for fetal lung maturation. (1, 18) Blood transfused was fresh, matched to the woman’s blood group, CMV negative, and irradiated, with haematocrit between 75-80%. IUTs
were performed under ultrasound guidance by appropriately trained staff.(1) The site of transfusion (umbilical cord, intrahepatic vein, or intra-peritoneal), and use of fetal paralysis was at the discretion of individual clinicians, in accordance with individual and institutional practices.(1, 19, 20) The transfused blood volume was determined considering gestational age, estimated fetal weight, and pre-transfusion haemoglobin,(1, 21) with a post transfusion specimen obtained where possible. The target post transfusion haemoglobin was a deficit of 4g/dL below the mean for gestational age.(6, 7) Following the procedure, monitoring of the fetal heart rate and uterine activity were undertaken.

Decisions relating to the timing of last IUT and of optimal timing of birth for women with red cell alloimmunisation are uncertain, with recommendations for birth ranging from after 32 weeks(22) to 36(23) or 38 weeks gestation.(1) In the context of this pragmatic trial, these decisions were made following discussion between the woman and her caregivers. At birth, a cord blood sample was taken to estimate haemoglobin, and/or haematocrit. Clinical outcomes were abstracted from case notes after birth. The woman and her caregivers were not blinded to treatment allocation, although where possible, staff assessing outcomes were blind to treatment allocation.

**Outcomes**

The primary outcome was infant cord blood haemoglobin at birth.

A range of secondary outcomes included:

1. Adverse infant outcomes related to alloimmunisation (one or more of stillbirth (intrauterine fetal death after trial entry and prior to birth); neonatal death (death of
a live-born infant before 28 days of age); severe fetal anaemia (at the time of second or any subsequent transfusion, defined as pre-transfusion haemoglobin ≥ 5 standard deviations below the mean for gestational age, with the mean Hb for gestational age defined according to the following formula:

\[ \text{Mean Hb} = 11 + (\text{GA weeks} - 17) \times 0.19 \];

(6) severe anaemia at birth (haemoglobin ≥ 5 standard deviations below the mean for gestational age); or neonatal exchange transfusion).

2. Procedure related complications necessitating emergency birth (including one or more of the following within one week of the procedure: preterm pre-labour ruptured membranes (PPROM); preterm labour; chorioamnionitis; placental abruption or antepartum haemorrhage).

3. Infant complications related to alloimmunisation (including preterm birth before 34 weeks gestation; jaundice requiring treatment; admission to the neonatal intensive care unit; neonatal top-up transfusion).

4. Maternal complications including antepartum haemorrhage or abruption; preterm premature rupture membranes; threatened preterm labour; chorioamnionitis.

5. Number of IUTs after randomisation.

**Sample Size**

The sample size and primary outcome were modified prior to finalising trial data, and before any of the planned analyses were performed, to account for slower than anticipated recruitment, and to be reflective of the available funding. Assuming a standard deviation in infant haemoglobin of 1g/dL, a sample of 35 participants per group (70 in total) provides 80% power (two-sided alpha=0.05) to detect non-inferiority with a non-inferiority margin of 0.6 g/dL.
The original sample size was 536 women, to detect a 30% reduction in a primary composite adverse outcome (stillbirth, neonatal death, severe fetal anaemia, severe anaemia at birth, neonatal exchange transfusion), with 5% significance level, and 90% power.

**Analysis and Reporting of Results**

Analyses used an intention-to-treat approach. Baseline characteristics of women were examined as an indication of comparable treatment groups, and included maternal age, race, height, weight, smoking history, and past obstetric history (including previous alloimmunised pregnancy; past preterm birth or perinatal loss related to alloimmunisation). No imputation was performed for missing data.

The effect of treatment was estimated using linear regression models for continuous outcomes, log binomial regression for binary outcomes, and log Poisson regression for count outcomes. Estimates are difference in means (MCA-PSV – Fall in Haematocrit), relative risk (MCA-PSV/Fall in Haematocrit) and rate ratio (MCA-PSV/Fall in Haematocrit) respectively, along with 95% confidence intervals. For number of transfusions, an offset was included for number of days between randomisation and delivery.

Both unadjusted and adjusted analyses were performed, adjusted analyses including the stratification variables presence of hydrops and antibody type (Kell vs other) as covariates. A small number of events were observed for many outcomes, which led to convergence issues with the models. Where there were too few events to allow for
adjustment, only unadjusted analyses were performed; where there were too few events for any modelling, a Fishers Exact test was performed.

**Trial Registration**

The trial was registered on the Australian and New Zealand Clinical Trials Register (ACTRN12608000643370).
RESULTS:
Between October 2009 and October 2013, 75 women were recruited. One woman had 3 affected pregnancies, with data pertaining to the first randomisation only included, and two women were randomised in error. A total of 71 women were randomised, 36 to the MCA-PSV Group, and 35 to the Fall in Fetal Hct Group (Figure 1). Baseline characteristics were similar between the two randomised groups (Table 1). The mean age of participating women was 33.6 years (± 4.7 years), and gestational age at randomisation 30.3 weeks (interquartile range (IQR) 27.7 to 32.00). Overall 60.6% of participants were Caucasian, and 25.4% were Hispanic. Most women were non-smokers (85.9%), had no evidence of fetal hydrops at first IUT (85.9%), with alloimmunisation antibodies other than Kell (90.1%).

There was one stillbirth (Fall in Fetal Hct Group) in a fetus with hydrops at 31 weeks, which occurred between randomisation and the scheduled second IUT, and 5 neonatal deaths (3 in the MCA-PSV group and 2 in the Fall in Fetal Hct group). Two infants in the MCA-PSV Group had hydrops and died following preterm birth, within the week following first IUT (29, and 30 weeks respectively), due to complications of prematurity. The third infant was born at 33 weeks gestation and died secondary to liver failure following multiple exchange and top-up transfusions in the postnatal period, and severe respiratory distress syndrome. One infant in the Fall in Fetal Hct Group required 5 IUTs, but died following preterm birth, and within one week of the last IUT at 28 weeks gestation. The infant’s haemoglobin at birth was 97g/dL, and complications of prematurity were compounded by an undiagnosed complex congenital cardiac lesion. The second infant was born at 33 weeks gestation within a week of the second IUT. Complications of prematurity were compounded by sepsis and multi-organ failure.
There were no statistically significant differences between the two treatment groups with regards to mean haemoglobin (MCA-PSV Group 103.6±38.2g/dL versus Fall in Fetal Hct Group 120.3±31.4g/dL; adjusted mean difference (aMD) -15.6; 95% CI -32.4 to 1.3; p=0.070), or mean number of IUTs after randomisation (MCA-PSV Group 1.75 (±1.79) versus Fall in Fetal Hct Group 1.80 (±1.32); adjusted relative risk aRR 0.88; 95% confidence interval (CI) 0.61 to 1.26; p=0.474) (Table 2). There were no statistically significant differences in gestational age at birth (MCA-PSV Group 35.23±2.30weeks versus Fall in Fetal Hct Group 35.07±2.28weeks; aMD 0.26; 95% CI -0.75 to 1.27; p=0.613); preterm birth before 34 weeks (MCA-PSV Group 9/36 (25.00%) versus Fall in Fetal Hct Group 7/35 (20.00%); aRR 1.36; 95% CI 0.61 to 3.05; p=0.458); or birth weight (MCA-PSV Group 2581.11±604.03g versus Fall in Fetal Hct Group 2602.69±591.34g; aMD -49.79; 95% CI -246.14 to 146.57; p=0.619). While a high proportion of infants were admitted to the neonatal unit, (MCA-PSV Group 28/35 (80.00%) versus Fall in Fetal Hct Group 22/34 (67.65%); aRR 1.20; 95% CI 0.89 to 1.60; p=0.231), there were no statistically significant differences in exchange transfusion (MCA-PSV Group 14/35 (40.00%) versus Fall in Fetal Hct Group 9/34 (26.47%); aRR 1.42; 95% CI 0.71 to 2.83; p=0.316); top-up transfusion (MCA-PSV Group 21/35 (60.00%) versus Fall in Fetal Hct Group 19/34 (55.88%); aRR 1.05; 95% CI 0.70 to 1.57; p=0.827); or jaundice requiring treatment MCA-PSV Group 29/34 (85.29%) versus Fall in Fetal Hct Group 30/34 (88.24%); aRR 1.06; 95% CI 0.91 to 1.22; p=0.460) (Table 2).

There were no statistically significant differences in procedure related or maternal complications (Table 3).
There was no evidence to suggest that outcomes varied according to the presence of hydrops at first IUT, or the responsible antibody (data not shown).
DISCUSSION:

Principal Findings

Doppler MCA-PSV measurement is not inferior to estimating the fall in fetal haematocrit to time second and subsequent IUTs, although infants born following Doppler MCA-PSV to time IUTs had a non-statistically significant trend towards lower mean haemoglobin at birth (103.6g/dL vs 120.3g/dL), and more frequent need for neonatal exchange transfusion (40.0% vs 26.5%). There were no significant differences identified with regards to other alloimmunisation or procedure related complications.

Comparisons with other studies

The procedure related complication risk in our trial was 2.8%, with an overall survival rate of 93%, both of which are consistent with the 3.1%, and greater than 90%, respectively reported in the literature.(20) In contrast, Zwiers and colleagues have recently reported their extensive 27-year experience involving almost 1,700 transfusion procedures, from a single tertiary referral centre.(24) In this cohort, survival improved from approximately 89% to 97%, and procedure related complications declined from 3.4% to 1.2% for the time periods 1998-2001 and 2001-2014 respectively. These high survival rates and low complication rates(24) are likely the “best case scenario”, reflective of both clinician experience and volume of procedures undertaken, as compared with the necessity of our more pragmatic study design.

Approximately 25% of infants in our trial had severe anaemia at birth, with 85% receiving phototherapy for treatment of jaundice. One third of infants received at least one exchange transfusion, and 60% at least one top-up transfusion. Infants in the MCA-PSV group tended to a lower haemoglobin at birth and were more likely to receive
exchange transfusion, when compared with estimating the fall in fetal haematocrit / haemoglobin. While these differences were not statistically significant, likely reflecting the sample size, they are clinically significant in neonatal care.

Neonatal outcomes reported from our trial are not directly comparable with other study populations reported in the literature. All infants in our trial population required at least one IUT, in contrast to other reports, where outcome comparisons have largely reflected the presence or absence of an antenatal transfusion procedure. Van Kamp reported neonatal outcomes for 191 infants born after any IUT. (25) While the mean haemoglobin reported at birth was consistent with our findings, it is difficult to compare other outcomes, with the median number of exchange and top-up transfusions reported, rather than an indication of the number of infants requiring this treatment. (25)

A study from the United Kingdom followed 28 women with MCA-PSV. (26) Reported neonatal complication rates were lower than identified in our trial with 36% of infants requiring phototherapy for jaundice, 25% an exchange transfusion, and 14% a top-up transfusion. (26) DeBoer and colleagues have reported outcomes for 89 infants with Rhesus haemolytic disease, where 52 infants required an IUT. (27) In this series, while 71% of infants who required an IUT also received an exchange transfusion, they required less phototherapy, but more top-up transfusions, when compared with infants who were not treated in the antenatal period, (27) although again, the comparator was infants who did not require an IUT.

Strengths & Weaknesses
To our knowledge, this is the first randomised trial evaluating Doppler MCA-PSV to
time second and subsequent IUTs for red cell alloimmunisation. We utilized robust
methodology, pre-specified relevant maternal and infant outcomes, and followed a pre-
specified analysis plan.

While the primary outcome and sample size was modified from the original trial
registration, this occurred prior to finalising data collection, before undertaking any pre-
specified analyses, and was made after accounting for slower than anticipated
recruitment and the final allocated funding. The trial is adequately powered to identify
relatively small differences in haemoglobin concentration at birth between the two
treatment practices, but not differences in less common clinical outcomes.

We encountered several barriers in conducting this trial, reflecting the need to involve
multiple centres internationally to study a relatively uncommon condition. We
experienced considerable delays in commencing recruitment, with the mean time to
obtain ethical approval in centres where recruitment occurred being 305 days (range 92
to 608 days). This delay was greater in centres where the ethical approval process was
commenced, but where recruitment did not occur (mean 518 days; range 153 to 1,095
days). Many clinical collaborators indicated that time pressures and a lack of research
support hampered their participation, although provision of dedicated research support
at each site was not possible with only modest financial reimbursement provided per
participant recruited. Unfortunately, there were considerable time delays between
investigators providing agreement to participate and securing funding. Over this time
there was a shift in clinical equipoise, such that many large referral centres
internationally routinely used MCA-PSV to time second and subsequent IUTs, and were therefore no longer willing to participate.

**Conclusions**

Our findings indicate that both Doppler MCA-PSV measurement and estimating the fall in fetal haematocrit or haemoglobin can be used to time second and subsequent IUTs. However, the trend towards lower infant haemoglobin, increased need for exchange transfusion, and the increased frequency of visits for ultrasound surveillance associated with MCA-PSV Doppler assessment, have resource implications for the woman, and healthcare facility, and are valid considerations in determining the most appropriate method to time IUTs.
ACKNOWLEDGEMENTS:

We are indebted to the women and their infants who participated in this randomised trial.

Each author fulfils the requirements for authorship and in particular all have been involved in the development and design of the trial, the conduct of the trial, drafting of the manuscript and revision for intellectual content, and gives approval of the final submitted version. JMD is the data custodian and accepts responsibility for the integrity of the trial and the data analyses. JMD and JL conducted the statistical analyses.

The following persons and institutions participated in the MCA Doppler Trial:

**Steering Group** – JM Dodd, C Andersen, JE Dickinson, RM Grivell, MD Kilby, R Windrim, G Ryan

**Co-ordinating Team** – JM Dodd, AR Deussen, RM Grivell, J Louise

**Statistical Analyses** – J Louise

**Writing Group** – JM Dodd, C Andersen, JE Dickinson, J Louise, AR Deussen, RM Grivell, L Voto, MD Kilby, R Windrim, G Ryan

**Recruiting hospitals and clinical collaborators** (total number of women recruited from each site in parentheses):

**Argentina:**

Fernandez Hospital, Buenos Aires (17): L Voto, G Voto, G Saa

**Australia:**

King Edward Memorial Hospital, Perth (3): JE Dickinson

Mater Mothers Hospital, Brisbane (2): G Gardener, J Thomas
Women’s and Children’s Hospital, Adelaide (7): JM Dodd, RM Grivell, P Muller, C Wilkinson, CA Crowther, AR Deussen, L Kannieappan

Belgium:
University of Leuven, Leuven (7): R Devlieger, A Gertis, J Richter, S Galjaard

Canada:
CHU Saint Justine, Montreal (1): F Audibert
Mt Sinai Hospital, Toronto (7): G Ryan, R Windrim, G Seaward, C Anastiadis
University of British Columbia (4): A Skoll, A Fernandez, D Cheema

Ireland:
National Maternity Hospital, Dublin (4): P McParland, R Moore, C Sreenan

New Zealand:
Auckland City Hospital, Auckland (7): E Parry, H Hauch
Wellington Women’s Hospital (1): J Tuohy, C Kell

United Kingdom:
Birmingham Women’s Hospital, Birmingham (10): MD Kilby, S Pretlove
The New Queen Elizabeth University, Glasgow (1): A Cameron, P Wu, S Court

DISCLOSURE STATEMENT:
The authors report no conflict of interest.

FINANCIAL SUPPORT:
This project was funded by a project grant from the National Health and Medical Research Council (NHMRC), Australia (ID 627195).
JM Dodd is supported through a NHMRC Practitioner Fellowship (ID 627005).
Infrastructure support was provided by The University of Adelaide.
The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
REFERENCES:


TABLE 1: Baseline characteristics of women enrolled in the trial by treatment group (MCA-PSV Group vs Fall in Fetal Haematocrit (Hct) Group)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>MCA-PSV Group N=36</th>
<th>Fall in Fetal Hct Group N=35</th>
<th>Overall N=71</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal Age: Mean (SD)</td>
<td>33.97 (4.78)</td>
<td>33.12 (4.67)</td>
<td>33.55 (4.71)</td>
</tr>
<tr>
<td>Type of Antibody: N (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Kell</td>
<td>2 (5.56)</td>
<td>5 (14.29)</td>
<td>7 (9.86)</td>
</tr>
<tr>
<td>- Other</td>
<td>34 (94.44)</td>
<td>30 (85.71)</td>
<td>64 (90.14)</td>
</tr>
<tr>
<td>Hydrops at First Transfusion: N (%)</td>
<td>5 (13.89)</td>
<td>5 (14.29)</td>
<td>10 (14.08)</td>
</tr>
<tr>
<td>Gestational Age (wks) at Randomisation</td>
<td>30.29 (27.79, 32.07)</td>
<td>30.29 (27.71, 31.86)</td>
<td>30.29 (27.71, 32.00)</td>
</tr>
<tr>
<td>Smoker: N (%)</td>
<td>5 (13.89)</td>
<td>5 (14.29)</td>
<td>10 (14.08)</td>
</tr>
<tr>
<td>Weight at Trial Entry (kg): Mean (SD)</td>
<td>70.22 (18.02)</td>
<td>71.63 (12.39)</td>
<td>70.93 (15.33)</td>
</tr>
<tr>
<td>Height at Trial Entry (kg): Mean (SD)</td>
<td>163.39 (5.89)</td>
<td>161.00 (6.76)</td>
<td>162.26 (6.37)</td>
</tr>
<tr>
<td>Ethnicity: N(%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Caucasian</td>
<td>22 (61.11)</td>
<td>21 (60.00)</td>
<td>43 (60.56)</td>
</tr>
<tr>
<td>- Hispanic</td>
<td>9 (25.00)</td>
<td>9 (25.71)</td>
<td>18 (25.35)</td>
</tr>
<tr>
<td>- Asian</td>
<td>2 (5.56)</td>
<td>2 (5.71)</td>
<td>4 (5.63)</td>
</tr>
<tr>
<td>- Other</td>
<td>3 (8.33)</td>
<td>3 (8.57)</td>
<td>6 (8.54)</td>
</tr>
<tr>
<td>Previous Pregnancies ≥20wks: Median (IQR)</td>
<td>3.00 (2.00, 3.50)</td>
<td>1.00 (1.00, 4.00)</td>
<td>2.00 (1.00, 4.00)</td>
</tr>
<tr>
<td>One or More Previous Pregnancies affected by Red Cell Alloimmunisation: N (%)</td>
<td>26 (74.29)</td>
<td>17 (53.13)</td>
<td>33 (64.18)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Of Pregnancies affected by Red Cell Alloimmunisation: N (%)*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Resulting in preterm birth</td>
<td>4 (15.38)</td>
<td>4 (23.53)</td>
<td>8 (18.60)</td>
</tr>
<tr>
<td>- Resulting in neonatal death</td>
<td>5 (19.23)</td>
<td>0 (0.00)</td>
<td>5 (15.15)</td>
</tr>
</tbody>
</table>

* Denominator is the number of women with a pregnancy previously affected by red cell alloimmunisation
**TABLE 2:** Fetal and neonatal outcomes related to alloimmunisation between the randomised treatment groups (MCA-PSV Group vs Fall in Fetal Haematocrit (Hct) Group)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>MCA-PSV Group (N=36)</th>
<th>Fall in Fetal Hct Group (N=35)</th>
<th>Unadjusted Treatment Effect (95% CI)</th>
<th>Unadjusted P-value</th>
<th>Adjusted Treatment Effect (95% CI)</th>
<th>Adjusted P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean cord blood haemoglobin at birth&lt;sup&gt;b&lt;/sup&gt;</td>
<td>103.62 (38.20)</td>
<td>120.26 (31.40)</td>
<td>-16.64 (-33.66, 0.38)</td>
<td>0.055</td>
<td>-15.58 (-32.43, 1.26)</td>
<td>0.090</td>
</tr>
<tr>
<td>Mean number of IUTs performed&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.75 (1.79)</td>
<td>1.80 (1.32)</td>
<td>0.88 (0.62, 1.25)</td>
<td>0.480</td>
<td>0.88 (0.61, 1.26)</td>
<td>0.474</td>
</tr>
<tr>
<td>Adverse fetal or neonatal outcome&lt;sup&gt;d&lt;/sup&gt;&lt;sup&gt;*,&lt;sup&gt;e&lt;/sup&gt;&lt;/sup&gt;</td>
<td>28 (82.35)</td>
<td>26 (78.79)</td>
<td>1.05 (0.83, 1.32)</td>
<td>0.713</td>
<td>1.06 (0.82, 1.37)</td>
<td>0.660</td>
</tr>
<tr>
<td>Severe fetal anaemia&lt;sup&gt;d&lt;/sup&gt;&lt;sup&gt;*,&lt;sup&gt;e&lt;/sup&gt;&lt;/sup&gt;</td>
<td>23 (65.71)</td>
<td>25 (75.76)</td>
<td>0.87 (0.64, 1.18)</td>
<td>0.365</td>
<td>0.90 (0.65, 1.25)</td>
<td>0.539</td>
</tr>
<tr>
<td>Fetal death&lt;sup&gt;v&lt;/sup&gt;</td>
<td>0 (0.00)</td>
<td>1 (2.86)</td>
<td>n/a&lt;sup&gt;l&lt;/sup&gt;</td>
<td>0.493</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Gestational Age at Birth</td>
<td>35.23 (2.30)</td>
<td>35.07 (2.28)</td>
<td>0.16 (-0.89, 1.21)</td>
<td>0.764</td>
<td>0.26 (-0.75, 1.27)</td>
<td>0.613</td>
</tr>
<tr>
<td>Mean Birthweight&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2581.11 (604.03)</td>
<td>2602.69 (591.34)</td>
<td>-21.57 (-295.76, 252.61)</td>
<td>0.877</td>
<td>-49.79 (-246.14, 146.57)</td>
<td>0.619</td>
</tr>
<tr>
<td>NICU Admission&lt;sup&gt;v&lt;/sup&gt;</td>
<td>28 (80.00)</td>
<td>23 (67.75)</td>
<td>1.18 (0.89, 1.57)</td>
<td>0.249</td>
<td>1.20 (0.89, 1.60)</td>
<td>0.231</td>
</tr>
<tr>
<td>Severe anaemia at birth&lt;sup&gt;v&lt;/sup&gt;</td>
<td>11 (34.38)</td>
<td>7 (22.58)</td>
<td>1.52 (0.68, 3.42)</td>
<td>0.308</td>
<td>1.40 (0.63, 3.13)</td>
<td>0.406</td>
</tr>
<tr>
<td>Neonatal Exchange Transfusion&lt;sup&gt;v&lt;/sup&gt;</td>
<td>14 (40.00)</td>
<td>9 (26.47)</td>
<td>1.51 (0.76, 3.02)</td>
<td>0.242</td>
<td>1.42 (0.71, 2.83)</td>
<td>0.316</td>
</tr>
<tr>
<td>Neonatal Top-up Transfusion&lt;sup&gt;v&lt;/sup&gt;</td>
<td>21 (60.00)</td>
<td>19 (55.88)</td>
<td>1.07 (0.72, 1.61)</td>
<td>0.729</td>
<td>1.05 (0.70, 1.57)</td>
<td>0.827</td>
</tr>
<tr>
<td>Jaundice requiring phototherapy&lt;sup&gt;v&lt;/sup&gt;</td>
<td>29 (85.29)</td>
<td>30 (88.24)</td>
<td>0.97 (0.80, 1.16)</td>
<td>0.721</td>
<td>1.06 (0.91, 1.22)</td>
<td>0.460</td>
</tr>
<tr>
<td>Neonatal death&lt;sup&gt;v&lt;/sup&gt;</td>
<td>3 (8.33)</td>
<td>2 (5.71)</td>
<td>1.46 (0.26, 8.21)</td>
<td>0.669</td>
<td>n/a&lt;sup&gt;l&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Perinatal death&lt;sup&gt;v&lt;/sup&gt;</td>
<td>3/36 (8.33)</td>
<td>3/35 (8.57)</td>
<td>0.97 (0.21, 4.50)</td>
<td>0.971</td>
<td>1.09 (0.26, 4.61)</td>
<td>0.905</td>
</tr>
</tbody>
</table>

<sup>a</sup> Adjustment for presence of hydrops at randomisation and antibody type (Kell vs other).
b Continuous outcomes: descriptives are mean and SD; estimates are difference in means (MCA-PSV – Control) and 95% CI

c Analysed using log Poisson regression; model included offset for number of days between randomisation and delivery

d Adjustment for antibody type only (no events in one hydrops category)

e Adjustment for hydrops only (no events in one Kell antibody category)

f Too few events to allow for modelling; P value from Fishers Exact test

g Only unadjusted results presented – too few events to allow for adjustment

* Adverse fetal or neonatal outcome, defined as one or more of severe fetal anaemia after randomisation, stillbirth, severe anaemia at birth, neonatal death, or need for neonatal exchange transfusion

^ Number and percentage
**TABLE 3:** Maternal antenatal and procedure related outcomes between the randomised treatment groups (MCA-PSV Group vs Fall in Fetal Haematocrit (Hct) Group)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>MCA-PSV Group (N=36)</th>
<th>Fall in Fetal Hct Group (N=35)</th>
<th>Unadjusted Treatment Effect (95% CI)</th>
<th>Unadjusted P-value</th>
<th>Adjusted Treatment Effect (95% CI)</th>
<th>Adjusted P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure related antenatal complication*</td>
<td>0 (0.00)</td>
<td>2 (5.71)</td>
<td>n/a*</td>
<td>0.239</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Threatened preterm labour</td>
<td>2 (5.56)</td>
<td>3 (8.57)</td>
<td>0.65 (0.12, 3.65)</td>
<td>0.623</td>
<td>0.66 (0.12, 3.72)*</td>
<td>0.638</td>
</tr>
<tr>
<td>Preterm Premature Ruptured Membranes</td>
<td>1 (2.78)</td>
<td>0 (0.00)</td>
<td>n/a*</td>
<td>&gt;0.99</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placental Abruption/Antepartum Haemorrhage</td>
<td>0 (0.00)</td>
<td>1 (2.86)</td>
<td>n/a*</td>
<td>0.493</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chorioamnionitis</td>
<td>0 (0.00)</td>
<td>1 (2.86)</td>
<td>n/a*</td>
<td>0.493</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preterm birth prior to 34 weeks gestation</td>
<td>9 (25.00)</td>
<td>7 (20.00)</td>
<td>1.25 (0.53, 2.99)</td>
<td>0.616</td>
<td>1.36 (0.61, 3.05)</td>
<td>0.458</td>
</tr>
<tr>
<td>Vaginal Birth</td>
<td>12 (33.33)</td>
<td>12 (34.29)</td>
<td>0.97 (0.51, 1.86)</td>
<td>0.932</td>
<td>0.93 (0.49, 1.77)</td>
<td>0.824</td>
</tr>
</tbody>
</table>

*aToo few events to allow for modelling; P value is from Fishers Exact test
b Adjusted for Hydrops only; could not adjust for antibody type due to presence of zero cell
c Adjusted for Kell antibody only; could not adjust for hydrops due to presence of zero cell

*Procedure related complication, defined as one or more of PPROM, preterm labour, chorioamnionitis, placental abruption or antepartum haemorrhage
**FIGURE 1:** Flow of participants through the trial.

- **75 Women Consented & Randomised**
  - **MCA-PSV Group** N=37
    - Excluded N=1
      - Included in Analyses N=36
  - **Fall Fetal Hct Group** N=38
    - Excluded N=3
      - Included in Analyses N=35